Specifically, we adapted the assay design to include measurements of monocyte subsets together with CD279+ CD8+ T cells, which may be useful parameters for predicting treatment-related hepatitis, clinical response to therapy or tumor staging (48, 49). This evidence concerns the gene PDCD1 and Hepatitis.